SHL Telemedicine Ltd., headquartered in Tel Aviv, a leading provider and
developer of advanced personal telemedicine solutions, and Shanghai Jiuchuan
Investment (Group) Co., Ltd., a Shanghai based private investment firm, announced today
that Shanghai Jiuchuan will acquire the entire share capital of SHL by way of a reverse
triangular merger following which SHL would become a wholly owned subsidiary of
Shanghai Jiuchuan.
After consummation of the merger, expected to happen in October, a delisting of SHL from
the SIX Swiss Exchange will take place.
SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the
provision of medical call center services, with a focus on cardiovascular and related diseases, to
end users and to the healthcare community. SHL Telemedicine offers its services and personal
telemedicine devices to subscribers utilizing telephonic and Internet communication technology.
The
Company operates in Israel, Germany, India and the United States in one business segment,
Telemedicine services. SHL is listed on the SIX Swiss Exchange and has an ADR program listed over-the counter.
Shanghai Jiuchuan Investment (Group) Co., Ltd. is a Shanghai based private investment firm having also
holdings in a company principally engaged in development in the medical science and technology
field.
No comments:
Post a Comment